Literature DB >> 12909199

Behavioral and biochemical investigations of bupropion metabolites.

Mikhail L Bondarev1, Tatiana S Bondareva, Richard Young, Richard A Glennon.   

Abstract

The stimulus effects of bupropion metabolites were examined in a drug discrimination procedure using (-)nicotine- and (+)amphetamine-trained rats. (+)- and (-)threohydrobupropion partially substituted in each group. R,R-hydroxybupropion produced vehicle-appropriate responding in (-)nicotine animals but, when given in combination with the training dose of (-)nicotine, resulted in an attenuated effect. S,S-Hydroxybupropion partially (66%) substituted for (-)nicotine. In (+)amphetamine-trained animals, S,S-hydroxybupropion (ED50=4.4 mg/kg) generalized completely and was similar in potency to bupropion (ED50=5.4 mg/kg). Bupropion and its metabolites lacked affinity for nicotinic acetylcholinergic receptors, but all antagonized (-)nicotine-induced 86Rb+ efflux in cells expressing alpha3beta4 nicotinic cholinergic receptors. S,S-Hydroxybupropion possessed affinity at the dopamine transporter comparable to bupropion, and was also found to bind at the norepinephrine transporter. Although it is unlikely that any metabolite isomer is chiefly responsible for the stimulus actions of bupropion, some probably play a role in the complex actions of this agent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12909199     DOI: 10.1016/s0014-2999(03)02010-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  40 in total

Review 1.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

2.  Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.

Authors:  Ronald J Lukas; Ana Z Muresan; M Imad Damaj; Bruce E Blough; Xiaodong Huang; Hernán A Navarro; S Wayne Mascarella; J Brek Eaton; Syndia K Marxer-Miller; F Ivy Carroll
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

Review 3.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 4.  Central nervous system biogenic amine targets for control of appetite and energy expenditure.

Authors:  David L Nelson; Donald R Gehlert
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

5.  Metabolism of bupropion by carbonyl reductases in liver and intestine.

Authors:  Jamie N Connarn; Xinyuan Zhang; Andrew Babiskin; Duxin Sun
Journal:  Drug Metab Dispos       Date:  2015-04-22       Impact factor: 3.922

6.  Examination of the metabolite hydroxybupropion in the reinforcing and aversive stimulus effects of nicotine in rats.

Authors:  E Malcolm; F I Carroll; B Blough; M I Damaj; M Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2015-03-13       Impact factor: 4.530

Review 7.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

8.  Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans.

Authors:  Jennifer E Sager; John R Choiniere; Justine Chang; Alyssa Stephenson-Famy; Wendel L Nelson; Nina Isoherranen
Journal:  ACS Med Chem Lett       Date:  2016-06-17       Impact factor: 4.345

9.  Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition.

Authors:  Evan D Kharasch; Amanda Crafford
Journal:  Clin Pharmacol Ther       Date:  2018-08-09       Impact factor: 6.875

10.  Identification of pharmacogenetic markers in smoking cessation therapy.

Authors:  Daniel F Heitjan; Mengye Guo; Riju Ray; E Paul Wileyto; Leonard H Epstein; Caryn Lerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-09-05       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.